SK Bioscience expands global health push, securing funding for RSV antibody

SK Bioscience expands global health push, securing funding for RSV antibody

SK Bioscience said Wednesday it has secured funding from the Research Investment for Global Health Technology Foundation to advance the clinical development of RSM01, a monoclonal antibody candidate aimed at preventing respiratory syncytial virus, strengthening its presence in the global infectious disease market. According to SK Bioscience, the RIGHT Foundation agreed to provide 4 billion won ($2.7 million) — the largest grant available per project — to the Korean vaccine developer. With the fu

By The Korea Herald